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and 1 year following initiation of LEN were identified in a US health plan claims
database (7/1/2007-6/30/2011). Persistence was defined as days from the first LEN
treatment to the earlier of either the date of discontinuation or end of the follow-up
period. Adherence was measured by the medication possession ratio. Indicators of
disease control included in this study were inpatient hospitalization(s) and number
of ER visits. Disease-related complications included evidence of skeletal-related
events (SREs) defined as fracture, spinal cord compression, or radiation to the bone;
and sepsis. RESULTS: Among the 605 patients meeting the inclusion criteria, per-
sistency with lenalidomide averaged 6.0 months (median  4.9) with 57.9% of
patients being persistent for the entire year. A one month increase in persistence
was associated with a lower probability of SREs (OR0.96; p0.078), sepsis
(OR0.86; p0.001), and relapse or disease progression (OR0.78; p0.001). The
probability of an inpatient hospitalization (OR0.68; p-value0.001) and additional
ER visits (OR0.83; p0.002) were both lower with better persistence. A higher
medication possession ratio measured in year 1 was associated with increased
overall survival (p0.007).CONCLUSIONS: This analysis demonstrates that contin-
uous treatment with LEN improves disease control in MM patients, as well as
reduces health care utilization and related costs as indicated by the lower risk of
hospitalizations and fewer ER visits.
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OBJECTIVES: Since 2008, teenage girls are being vaccinated against Human Papil-
lomavirus (HPV) in Europe. The vaccine coverage did not reach high uptake. The
aim of this study is to design a dynamic transmission framework to model HPV-
transmission in the population in order to predict epidemiologic and economic
consequences of population-based HPV vaccination programs. METHODS: A dy-
namic transmission model was designed including 7 different HPV-types to predict
the epidemiologic and economic consequences of HPV-vaccination. Dutch age-
specific HPV-prevalence and cervical cancer incidence and mortality data were
used to calibrate the model assuming a steady state. The consequence of HPV-
vaccination was analyzed in different scenarios. In particular, the age of the vac-
cinee, inclusion of boys, and a reduced screening compliance was assessed. In
sensitivity analyses, the vaccination coverage, duration of vaccine-induced protec-
tion, and vaccine choice was varied. RESULTS: Vaccination of 50% of girls against
HPV infection results in a 56% overall reduction in cervical cancer incidence. The
model predicted outcomes are highly sensitive for the duration of vaccine-induced
protection and the vaccination coverage. If vaccination will only provide 20-years
of protection a 32% reduction in cervical cancer incidence was observed. HPV16 and
18 will be eradicated from the general population if vaccine coverage is 90%.
Vaccination at an older age still provides a relevant number of cases averted how-
ever vaccination before sexual debut remains most efficient. Vaccination of boys
was found to be not an effective alternative. CONCLUSIONS: HPV vaccination was
found to be highly effective in reducing the burden of cervical cancer. The model
predicted outcomes are most sensitive for vaccine-induced duration of protection.
Vaccination of girls at an older age can be considered to further reduce the inci-
dence of cervical cancer.
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OBJECTIVES: The worldwide incidence of melanoma is increasing rapidly. Two
chemotherapy regimens are used for treatment of Malignant Melanoma: single
agent intravenous Dacarbazine (DTIC) and oral Temozolomide (TMZ). TMZ has
greater cost in Iran so we aimed to conduct a meta analysis to compare the efficacy
of two drugs. METHODS: To compare the efficacy of these two drugs, a systematic
review and meta-analysis were conducted and published articles, comparing use
of Dacarbazine and Temozolomide in treatment of Malignant Melanoma were re-
viewed. For this purpose, Pubmed, Scopous, Web of Science and Cochrane Central
Register of Controlled Trials were searched and the search terms were: “Dacarba-
zine” and “Temozolomide” and “ Malignant Melanoma”. Data were collected from
inception to 2012. “Response to treatment” includes:” complete response (CR)”,”
partial response (PR)” and “stable disease (SD)” and side effects were the key out-
comes of interest. RESULTS: The meta-analysis included 3 RCTS and involved 1314
patients with malignant melanoma. Approximately half of them were allocated to
the TMZ arm and half to the DTIC arm. Comparison of TMZ with DTIC yielded a
nonsignificant relative risk (RR) of 0.83 (95% confidence interval of 0.26-2.64,
P0.76) for complete response. A nonsignificant RR of 1.35 (95% CI of 0.95-1.91,
P0.1) for partial response. A nonsignificant RR of 1.05 (95% CI of 0.85-1.3, P0.65)
for stable disease and a nonsignificant RR of 1.15 (95% CI of 0.74-1.79, P0.55) for
fatigue ( a side effect). CONCLUSIONS: The potential value of oral versus intrave-
nous chemotherapy is obvious but considering health outcome and not significant
difference in efficacy between these two drugs and that TMZ even does not have
less side effects and has higher cost of treatment in Iran, we suggest DTIC as a
first-choice treatment for Malignant Melanoma.
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OBJECTIVES: To systematically review the currently available clinical and cost-
effectiveness evidence on proton beam radiotherapy (PBRT) for cancers mostly
affecting the eye: uveal melanoma, retinoblastoma and metastatic tumors.
METHODS: A systematic literature search was conducted for published and un-
published cost-effectiveness and clinical data (comparative studies) on the eye
cancer population, treated with proton radiation, using a number of medical data-
bases (PubMed, EMBASE, Cochrane Library). In addition, clinical trial registries
were searched, reference lists of included studies and of reviews were screened for
missed studies. Searches took place in January 2012. RESULTS: The search gener-
ated 374 references, of which 5 comparative studies met the inclusion criteria. All
were reporting cases of uveal melanoma. Studies were characterized by large dif-
ferences in radiation techniques applied within the studies, and by variation in
patient characteristics within and between studies. Overall, the level of evidence is
low. When compared to iodine-125 or ruthenium-106 brachytherapy, protons did
not provide beneficial effects on overall survival. Proton therapy was although
superior to enucleation: results of two studies showed that 12% more patients
survived over 36 months and 21% more patients survived over 60 months in the
proton group. Vision preservation was observed significantly more frequently after
proton therapy than iodine-125 brachytherapy (97% vs 93.1%, p0.009). Only one
included study reported side effects. Refractory neovascular glaucoma and corneal
perforations were observed after proton therapy and 10.9% eyes treated with PBRT
were enucleated due to complications. No economic evaluation studies were
found. CONCLUSIONS: There is limited evidence on the effectiveness and safety of
proton radiation in patients with ocular melanomas due to the lack of well-de-
signed and well-reported studies. Available comparative studies suggest that pro-
ton beam therapy may be beneficial for patients with uveal melanoma, with, how-
ever, possible serious side effects. There is a need for research establishing its
cost-effectiveness.
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OBJECTIVES: To compare clinical efficacy and safety of sunitinib (SUN) and best
supportive care (BSC) versus placebo (PL) and best supportive care (BSC) in the
treatment of patients with unresectable or metastatic, well-differentiated pancre-
atic neuroendocrine tumours (pNET) with disease progression. METHODS: The
review was conducted in accordance with the Cochrane Collaboration guidelines
and the Polish Agency for Health Technology Assessment (AOTM) recommenda-
tions. Calculations were performed using the StatsDirect® 2.6.8 statistical package.
RESULTS: As a result of systematic search of publications, 1 primary randomized
clinical trial (subtype II A), satisfying the inclusion criteria was found (Raymond
2011). It was shown that the use of SUNBSC results in a statistically significant
higher clinical efficacy in respect of progression free survival (PFS), overall survival
(OS) and objective response rate in comparison with the control (PLBSC). The
median PFS was over two fold greater in sunitinib treated patients (11.4 months)
than in placebo group (5.5 months). The objective response rate was 9.3% in the
sunitinib group versus 0% in the placebo group. In the sunitinib group 9 deaths
(10%) were reported compared with 21 deaths (25%) in the placebo group (HR 0.40;
95% CI, 0.18 to 0.86). Sunitinib is safe and well-tollerated therapy. The most fre-
quent adverse events in the sunitinib group were diarrhea, nausea, vomiting, as-
thenia, and fatigue. In most cases, analysed adverse events were of low severity
grade. CONCLUSIONS: The results of the presented analysis clearly prove that
sunitinib administered in a 37,5 mg dose is an effective and safe therapy in the
treatment of patients with unresectable or metastatic, well-differentiated pancre-
atic neuroendocrine tumours with disease progression.
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OBJECTIVES: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine ki-
nase inhibitor (TKI) that has proven, in controlled clinical trials, to be effective in
the first-line treatment of patients with advanced or metastatic non-small-cell
lung cancer (mNSCLC) with EGFR activating (EGFR) mutations, showing signifi-
cant improvement of progression-free survival over platinum-based standard che-
motherapy. In those trials, pemetrexed was not included in the platinum-based
chemotherapy regimens used as a comparator, since it was not yet approved for
first line use. Following approval as first line treatment for lung adenocarcinoma,
plus cisplatin, it became the standard for this indication. The aim of this analysis
was to compare the efficacy in reducing the risk of disease progression for patients
with mNSCLC with EGFR mutations treated with erlotinib versus pemetrexed/
cisplatin. METHODS: In the absence of head-to-head trials comparing erlotinib
with pemetrexed/ cisplatin, an indirect comparison methodology was performed
using the Hazard Ratio (HR) - the most appropriate measure to compare time re-
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